

ASX Release

APPENDIX 4C: FINAL QUARTER FY 2019

PERTH, AUSTRALIA – 31 July 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated Group for the final quarter of FY2019.

In June, the company raised \$3.9m via a rights issue and additional placement. The net outflow from operating activities for the quarter was \$797,000. The bank balance at 30 June 2019 was \$4,314,000.

The quarter to 30 June saw a number of key developments for the company:

- SUDA restructured the board of directors bringing on David Simmonds and Paul Hopper as Non-executive directors and changing the role of David Phillips to that of an executive director.
- We lodged our Marketing Approval Authorisation for ZolpiMist with the Australian Therapeutic Goods Administration.
- The new SUDA website was launched and an increased focus in communications was initiated.
- Working with our advisors, CPS, SUDA raised \$3.9M through a rights issue and placement
- SUDA entered into a binding term sheet for a second cannabinoid deal and expects to finalise the agreement in the current quarter.
- We expanded our Business Development coverage through the engagement of two groups in the US and Asia.
- We announced that the European Patent Office had informed SUDA of its intention to grant our anagrelide patent in the use of cancer.

Mr Stephen Carter, SUDA's CEO, commented: "The final quarter of FY 2019 was dominated by the major changes to the Board with a new chairman and the successful completion of the rights issue. With the changes that we have been implementing at both board and strategic management level we expect the beginning of the 2019-20 financial year to be very exciting with completion of a number of negotiations. We further believe that our increased focus on communication and investor relations will become more apparent and provide our shareholders with a greater degree of understanding of the process and progress of our programmes."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Suda Pharmaceuticals Ltd

ABN

35 090 987 250

Quarter ended ("current quarter")

30 June 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	118	1,051
1.2 Payments for		
(a) research and development	(97)	(173)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(277)	(1,099)
(f) administration and corporate costs	(545)	(1,760)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	6	30
1.5 Interest and other costs of finance paid	(2)	(166)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	745
1.8 Other (second instalment in settlement of HC Berlin Pharma matter)		(1,271)
1.9 Net cash from / (used in) operating activities	(797)	(2,643)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(2)	(296)
(b) businesses (see item 10)	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(c) investments	-	-
(d) intellectual property	(255)	(1,095)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(257)	(1,391)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	3,898	10,687
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(237)	(435)
3.5 Proceeds from borrowings	-	140
3.6 Repayment of borrowings	-	(2,142)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	3,661	8,250

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,707	98
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(797)	(2,643)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(257)	(1,391)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,661	8,250
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	4,314	4,314

5. Reconciliation of cash and cash equivalents	Current quarter \$A'000	Previous quarter \$A'000
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1 Bank balances	3,814	807
5.2 Call deposits	500	900
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,314	1,707

6. Payments to directors of the entity and their associates

6.1 Aggregate amount of payments to these parties included in item 1.2

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
181
-

Salaries, consulting fees and directors' fees paid for the current quarter.

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

--

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (Convertible Notes)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(108)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	(305)
9.6 Administration and corporate costs	(520)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(933)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Director/Company secretary)

Date: 31 July 2019.....

Print name:Stephen Carter.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.